Core Insights - The Beijing Municipal Health Commission has issued the "Action Plan for Supporting the Development of Artificial Intelligence Applications in the Medical and Health Field (2026-2027)" and "Several Measures to Support the Innovative Development of the Artificial Intelligence Industry in the Medical and Health Field (2026-2027)" [1] Group 1: Action Plan Overview - The Action Plan focuses on three dimensions: core application scenarios, expanding application scenarios, and increasing support and guarantee efforts, deploying 16 key tasks [2] - Key tasks include promoting clinical diagnosis assistance, grassroots health, and health management, encouraging collaboration between medical institutions and quality AI companies, and constructing a new paradigm for drug and device research and development driven by AI technology [2][3] Group 2: Measures for AI Development - The Measures outline four dimensions: focusing on clinical demand scenarios, strengthening data governance, optimizing support systems, and enhancing policy guarantees, deploying 15 key tasks [4] - The goal is to create a full-process research and application model for medical AI products, aiming for breakthroughs in cutting-edge AI technologies in healthcare and mutual empowerment of the industry by 2027 [4]

2025年12月30日，北京未来医药产业链研究院成立仪式在北京市昌平区举行。 工业和信息化部消费品工业司、北京市经济和信息化局和昌平区委、区政府相关领导，医药领域全国性 行业协会和部分研究机构、骨干企业代表等共100余人齐聚现场，共同见证研究院揭牌启航。 北京未来医药产业链研究院是在工业和信息化部消费品工业司指导推动下，由医药领域多家全国性行业 协会、研究机构、重点企业联合发起成立的标杆性医药产业链服务平台。研究院聚焦四大职能定位：打 造全球领先的医药产业战略智库，着力开展行业运行分析和前瞻性战略研判；打造行业认可的医药科技 成果转化平台，推动加快医药科技创新成果产业化；打造高效联动的医药全产业链协作促进平台，促进 产业链大中小企业合作对接和产业链各环节高效协同；打造国际一流的医药产业国际合作平台，为我国 医药产业链深度融入全球体系和全球医药产业合作提供有力支撑。 工业和信息化部消费品工业司主要负责同志在致辞中指出，组建北京未来医药产业链研究院是落实医药 工业产业链高质量发展行动的重要举措，对推进医药工业产业链高质量发展、打造生物医药新兴支柱产 业具有深远意义。研究院作为促进各方深化合作、强链聚能重要的载体， ...

Core Viewpoint - The National Medical Products Administration (NMPA) of China has released the "Priority Approval Catalog for High-end Medical Devices (2025 Edition)", which includes eight advanced medical devices for expedited approval, aiming to accelerate the market entry of innovative high-end medical equipment [1]. Group 1: Priority Approval Catalog - The catalog includes advanced medical devices such as the boron neutron capture therapy system, ultra-high field magnetic resonance imaging equipment, medical electron accelerators, and implantable brain-machine interface devices [1][2]. - The NMPA will implement priority approval for the medical devices listed in the catalog according to Article 73, Item 3 of the "Regulations on the Registration and Filing of Medical Devices" [1][5]. Group 2: Device Specifications - The boron neutron capture therapy system is designed to treat malignant tumors that are recurrent or for which there are no other conventional treatment options, utilizing a reaction between neutrons and boron to produce secondary particles that kill cancer cells [2]. - The ultra-high field magnetic resonance imaging equipment has a magnetic field strength greater than 5 Tesla [2]. - The medical electron accelerator integrates magnetic resonance imaging guidance and is used for various therapeutic applications [2]. - The implantable brain-machine interface device captures neural signals from the central nervous system through implanted electrodes, enabling interaction with external control devices for compensating motor and sensory dysfunctions [2]. - The endoscopic surgical control system employs robotic technology for operating surgical instruments through natural orifices [2]. - The transcatheter tricuspid valve repair system is suitable for high-risk patients with severe tricuspid regurgitation who are deemed unsuitable for surgical intervention [2]. - The minimally invasive glaucoma surgery (MIGS) implant establishes a drainage pathway for aqueous humor in the eye [2].

| 序号 | 板块 | 涨跌幅(%)▼ | 总成交量(万手) = 总成交额(亿元) ▼ | | 净流入 (亿元) ▼ | 上涨家数 | 下跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 文化传媒 | 2.75 | 3016.13 | 347.75 | 65.98 | 76 | 8 | | 2 | 教育 | 1.72 | 574.99 | 35.02 | 1.82 | 12 | ഗ | | 3 | 军工电子 | 1.33 | 1688.54 | 434.15 | 3.59 | 46 | 15 | | 4 | IT服务 | 1.30 | 2145.81 | 315.05 | 12.39 | વેર | 33 | | 5 | 通信服务 | 1.30 | 640.45 | 102.64 | 10.68 | 36 | ಡ | | 6 | 软件开发 | 1.21 | 1492.12 | 342.89 | 24.55 | 109 | 29 | | 7 | 互联网电商 | 1.00 | 166.51 | 20.58 | 1.01 | 11 | 6 | ...

Core Viewpoint - The 2026 China Exhibition Economy International Cooperation Forum (CEFCO Forum) will be held from January 21 to 23, 2026, in Wuhan, Hubei Province, focusing on high-quality development in the exhibition industry [1][2]. Group 1: Event Details - The theme of the 2026 forum is "Transformative Era: Co-creating Links, Innovating the Future" [1]. - The forum is co-hosted by the China Council for the Promotion of International Trade and four international exhibition organizations [1]. - Over 20 countries and regions have confirmed participation from exhibition institutions, enterprises, and experts [1]. Group 2: Agenda and Topics - The opening ceremony and the first plenary session will take place on the morning of January 22, 2026, followed by the second plenary session on January 23 [1]. - Key topics include the integration of exhibitions with industries, new paradigms for international exhibitions, evaluation factors for quality exhibitions, cooperation in the Greater Bay Area, digital transformation in the exhibition industry, and ESG practices [1]. - Six breakout sessions will be held to discuss these topics in detail [1]. Group 3: Reports and Agreements - During the forum, the China Council for the Promotion of International Trade will release the "China Exhibition Economy Development Report 2025" [2]. - A series of exhibition cooperation project signing ceremonies will also take place [2].

Core Insights - The article highlights the evolution of Zhuoyu Technology from its inception in 2016 to its current status as a leading player in the autonomous driving industry, emphasizing its commitment to creating advanced robotic solutions [1][2][3] Company Development - Zhuoyu Technology transitioned from being a part of DJI to an independent entity in September 2024, facing financial pressures and the challenge of becoming a self-sustaining market player [2] - The company has grown to serve nine major clients in the passenger vehicle sector, covering over 50 models and expanding its reach into commercial vehicles and logistics [2][3] Technological Advancements - Zhuoyu has shifted from a rule-based approach to an end-to-end model in autonomous driving, overcoming engineering challenges and achieving breakthroughs in L2+ assistance technology [4][6] - The company has developed a unique capability to optimize computing power and sensor efficiency, allowing it to offer competitive products at lower costs compared to industry standards [4][5] Market Position - Zhuoyu's business model integrates hardware and software, resulting in significantly higher revenue per vehicle compared to competitors, establishing a strong foothold in the intelligent driving market [5][6] - The company aims to democratize access to intelligent driving features, making them available in lower-cost vehicles, thus challenging the perception of being a "price butcher" in the industry [4][6] Future Vision - Zhuoyu is focused on building a "space intelligent mobility foundation" to lead the autonomous mobile robot era, expanding its capabilities beyond passenger vehicles to include heavy trucks and unmanned logistics vehicles [7][8] - The company has initiated projects for heavy truck highway navigation and is collaborating with leading firms to design unmanned logistics vehicles for various applications [7][8]

中国经济网北京12月31日讯 国家金融监督管理总局网站昨日公布的合川监管分局行政处罚信息公 开表（合川金管罚决字〔2025〕3号）显示，重庆农村商业银行股份有限公司合川分行内控管理失效； 贷前调查不尽职。合川金融监管分局对其罚款80万元。 石少林（时任重庆农村商业银行股份有限公司合川分行风险管理部合规审查岗兼注销登记复审岗） 对内控管理失效的违法违规行为负有责任。合川金融监管分局对其警告。 以下为原文： | 序 | 当事人名称 | 行政处罚决 | 主要违法违规 | 行政处罚 | 作出决定 | | --- | --- | --- | --- | --- | --- | | 릉 | | 定书文号 | 行为 内控管理失 | 内容 | 机关 | | 1 | 重庆农村商业银行股 | | 效:贷前调查 | 罚款80万 元 | | | | 份有限公司合川分行 | | 不尽肥 | | | | | 杨凤麒(时任重庆农 | | | 禁止从事 | | | 2 | 商行合川分行城西支 | | 内控管理失效 | 银行业工 | | | | 行客户经理) | | | 作终身 | | | | 罗静(时任重庆农村 | | | 警告并罚 | | ...

本次向特定对象发行股票的发行对象为不超过35名特定投资者。所有发行对象均以同一价格认购本次向特定对象发行股票，且均以现金方式认购。 本次向特定对象发行股票的发行价格不低于定价基准日前二十个交易日公司股票交易均价的80%，且不低于定价基准日前公司最近一期经审计的归属于 母公司普通股股东的每股净资产值。 本次向特定对象发行股票数量按照本次向特定对象发行募集资金总额除以发行价格计算得出，且发行数量不超过1,813,840,599股（含本数），同时不超 过本次向特定对象发行前公司总股本的30%。 中国经济网北京12月31日讯 上交所网站审核项目动态昨日显示，中华企业(600675.SH)2023年度向特定对象发行A股股票获审核通过。 2025年7月16日，中华企业披露《2023年度向特定对象发行A股股票预案(二次修订稿)》。本次发行股票募集资金总额预计不超过133,000.00万元（含本 数），扣除发行费用后拟用于以下项目：中企誉品·银湖湾、中企云萃森林。 | | | | 单位: 万元 | | --- | --- | --- | --- | | 库号 | 项目名称 | 项目总投资 | 拟投入募集资金 | | | 架梁 ...

Core Viewpoint - The announcement details the effective contract of the Huaxia CSI 300 Index Quantitative Enhanced Securities Investment Fund, highlighting its fundraising success and management details [1][2]. Fund Details - Fund Name: Huaxia CSI 300 Index Quantitative Enhanced Securities Investment Fund [2] - Fund Code: 025480 [2] - Fund Type: Contractual open-end fund [2] - Effective Date of Fund Contract: December 30, 2025 [2] - Fund Manager: Huaxia Fund Management Co., Ltd. [2] - Fund Custodian: China Construction Bank Co., Ltd. [2] Fundraising Information - Total Net Subscription Amount during Fundraising: 1,342,513,165.00 RMB [1][3] - Interest Earned during Fundraising Period: 453,054.39 RMB [1][3] - Total Fund Shares: 1,342,966,219.39 shares [1][3] - Number of Valid Subscription Accounts: 22,251 [3] Management Team - Proposed Fund Manager: Jing Boling, who joined Huaxia Fund Management in July 2016 and has held various positions including researcher and assistant fund manager [1].

中国经济网北京12月31日讯 今日，华商基金发布华商安元债券型证券投资基金基金合同生效公 告。 | 位:份) 利息结 | | | | | --- | --- | --- | --- | | 转的份 538,537.11 | | 295, 550. 57 | 834,087.68 | | 额 | | | | | 合计 | 1, 272, 339, 429. 81 | 832, 405, 831. 40 | 2, 104, 745, 261. 21 | (责任编辑：康博) 募集期间净认购金额2,103,911,173.53元，认购资金在募集期间产生的利息834,087.68元，募集份额 合计2,104,745,261.21份。 该基金拟任基金经理胡中原2014年7月加入华商基金管理有限公司，曾任证券交易部债券交易员、 投资管理部基金经理助理、多资产投资部(原固定收益部)总经理助理；2018年1月2日至2019年12月19日 担任华商现金增利货币市场基金的基金经理助理；2019年3月19日起担任基金经理。 | 基金募集申请获 | | | | | | --- | --- | --- | --- | --- | | 中 ...